Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2000-6-27
pubmed:abstractText
The mechanisms leading to a relative dominance of T cells producing type 2 cytokines in certain human immune disorders are still unclear. We investigated the relative susceptibility to apoptosis induced by primary in vitro activation of human type 1 (producing interferon-gamma (IFN-gamma)) or type 2 (producing IL-4) T cells. Peripheral blood lymphocytes were isolated from patients with immune disorders characterized by expansion of type 2 cells (four with AIDS and hyper-IgE/hypereosinophilia, one with Churg-Strauss syndrome, and one with idiopathic hypereosinophilic syndrome) or from individuals with normal cytokine balances. Cells were stimulated for 16 h with ionomycin and phorbol ester, and apoptosis of cytokine-producing cells was assessed by flow cytometry. T cells with a type-2 cytokine profile, i.e. producing IL-4 alone, were significantly more resistant to activation-induced apoptosis than those producing IFN-gamma alone. This was observed in AIDS patients, whose type 2 cells were mostly CD8+, as well as in the patients with Churg-Strauss and with hypereosinophilic syndrome. CD4+ and CD8+ IL-4-producing cells were equally resistant to apoptosis. Lower susceptibility to apoptosis of type-2 T cells was also observed in subjects with normal cytokine balances. Bcl-2 expression was high in type-2 cells and in viable type-1 cells, whereas it was low in apoptotic type-1 cells. Resistance to activation-induced apoptosis may explain the expansion of cells producing type-2 cytokines in certain immune disorders.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-1373086, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-1400587, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-7509654, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-7530039, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-7536767, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-7595228, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-7632949, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-7807023, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8023142, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8023143, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8046328, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8096699, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8129773, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8302319, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8525383, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8596933, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8608231, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8617299, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8617980, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8805678, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8811042, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8820272, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-8893001, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9002959, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9034138, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9143690, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9151709, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9159150, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9190907, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9207455, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9233457, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9257779, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9295019, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9344501, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9378492, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9531275, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9577091, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9602313, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9647260, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9686584, http://linkedlifedata.com/resource/pubmed/commentcorrection/10844523-9834059
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0009-9104
pubmed:author
pubmed:issnType
Print
pubmed:volume
120
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
454-62
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Human T cells with a type-2 cytokine profile are resistant to apoptosis induced by primary activation: consequences for immunopathogenesis.
pubmed:affiliation
Department of Clinical Medicine, University of Rome 'La Sapienza', Rome, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't